HK1246640A1 - 硫酸葡聚糖的新用途 - Google Patents

硫酸葡聚糖的新用途 Download PDF

Info

Publication number
HK1246640A1
HK1246640A1 HK18106000.5A HK18106000A HK1246640A1 HK 1246640 A1 HK1246640 A1 HK 1246640A1 HK 18106000 A HK18106000 A HK 18106000A HK 1246640 A1 HK1246640 A1 HK 1246640A1
Authority
HK
Hong Kong
Prior art keywords
dextran sulfate
pharmaceutically acceptable
acceptable salt
subject
fibrosis
Prior art date
Application number
HK18106000.5A
Other languages
English (en)
Chinese (zh)
Inventor
L‧布鲁斯
L‧布魯斯
A‧布鲁斯
A‧瓦斯
A‧布魯斯
Original Assignee
Tx医生公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tx医生公司 filed Critical Tx医生公司
Publication of HK1246640A1 publication Critical patent/HK1246640A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HK18106000.5A 2015-07-30 2016-07-15 硫酸葡聚糖的新用途 HK1246640A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1551050-6 2015-07-30
SE1551050A SE539575C2 (en) 2015-07-30 2015-07-30 Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
PCT/SE2016/050720 WO2017018922A1 (en) 2015-07-30 2016-07-15 New use of dextran sulfate

Publications (1)

Publication Number Publication Date
HK1246640A1 true HK1246640A1 (zh) 2018-09-14

Family

ID=57884849

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106000.5A HK1246640A1 (zh) 2015-07-30 2016-07-15 硫酸葡聚糖的新用途

Country Status (11)

Country Link
US (1) US10478451B2 (enExample)
EP (1) EP3328395B1 (enExample)
JP (1) JP6837679B2 (enExample)
CN (2) CN107921055A (enExample)
BR (1) BR112018001942A2 (enExample)
DK (1) DK3328395T3 (enExample)
EA (1) EA034313B1 (enExample)
ES (1) ES2882115T3 (enExample)
HK (1) HK1246640A1 (enExample)
SE (1) SE539575C2 (enExample)
WO (1) WO2017018922A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3532072T3 (pl) * 2017-05-17 2020-09-21 Tx Medic Ab Leczenie jaskry
WO2018212708A1 (en) * 2017-05-17 2018-11-22 Tx Medic Ab Treatment of glaucoma
ES2999371T3 (en) * 2017-09-08 2025-02-25 Tx Medic Ab New use of dextran sulfate
AU2019232163B2 (en) * 2018-03-09 2025-11-20 Carmeda Ab Improvements to processes for immobilising biological entities
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation
SE544447C2 (en) * 2020-09-29 2022-05-31 Tx Medic Ab Treatment of fatty liver diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
EP0868191A1 (en) 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
US20040224922A1 (en) 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
SE525461C3 (sv) * 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
WO2007028053A2 (en) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
WO2007075388A2 (en) * 2005-12-15 2007-07-05 X-Cell Medical Incorporated Methods of locally treating and preventing cardiac disorders
WO2008134430A1 (en) 2007-04-24 2008-11-06 Novelmed Therapeutics Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
WO2011091167A2 (en) * 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
DK2768522T3 (en) * 2011-10-18 2016-11-14 Csl Behring Gmbh The use of sulfated glycosaminoglycan for improving the bioavailability of blood coagulation factors.
CN102973593A (zh) 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗肝纤维化药物中的应用
WO2015190989A1 (en) * 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
CA2951686C (en) * 2014-06-12 2019-05-21 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenesis in a subject

Also Published As

Publication number Publication date
EA201890212A1 (ru) 2018-06-29
JP6837679B2 (ja) 2021-03-03
BR112018001942A2 (pt) 2018-09-18
CN107921055A (zh) 2018-04-17
DK3328395T3 (da) 2021-08-09
SE539575C2 (en) 2017-10-17
WO2017018922A1 (en) 2017-02-02
JP2018521086A (ja) 2018-08-02
EP3328395A1 (en) 2018-06-06
CN114712385A (zh) 2022-07-08
EP3328395A4 (en) 2018-06-20
US10478451B2 (en) 2019-11-19
SE1551050A1 (en) 2017-01-31
ES2882115T3 (es) 2021-12-01
EP3328395B1 (en) 2021-06-09
EA034313B1 (ru) 2020-01-28
US20180221403A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
US10478451B2 (en) Use of dextran sulfate
US6331298B1 (en) Wound healing and treatment of fibrotic disorders
JP6837835B2 (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
US10925890B2 (en) Use of dextran sulfate
US20160317570A1 (en) Alginate biomaterials for the treatment of hepatic disorders
JP5508853B2 (ja) 糖尿病性神経障害における末梢神経の形態機能的回復のための上皮増殖因子の使用
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
Jiménez Gallo et al. Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine
US20230310322A1 (en) Pfd loaded microspheres and method for preparing injectable composite microsphere hydrogel solution from same
JP2002538087A (ja) 薬学的調製物を製造するためのオロソムコイドの使用
EP3920957A1 (de) Kardioprotektiver effekt des vasokonstriktion-inhibierenden faktors (vif)
CN118001374A (zh) 一种抗皮肤纤维化的药物
Kim et al. Drug Elimination Kinetics in the Eye after Subconjunctival Delivery
SE1451120A1 (sv) Use of dextran sulfate for inducing angiogenesis
JPH06321801A (ja) 消化管粘膜障害の予防及び治療剤